Genetic similarities between johnsongrass and grain sorghum leave producers with limited herbicide options for postemergence johnsongrass control. TamArk TM grain sorghum with resistance to acetyl-CoA carboxylase-inhibiting herbicides was developed through a collaboration between the University of Arkansas System Division of Agriculture and Texas A&M AgriLife Research. Two field experiments were conducted in 2021 in two locations each: Keiser and Marianna, AR, or Fayetteville and Marianna, AR. The objective of the first was to determine the optimal rate and application timing of fluazifop-butyl for control of natural johnsongrass populations in a noncrop setting, and the objective of the second was to evaluate johnsongrass control and TamArk TM grain sorghum tolerance in response to fluazifop-butyl applied at different timings and rates based on crop growth stage. The highest levels of johnsongrass control occurred when sequential applications of fluazifop-butyl were utilized. All sequential treatments provided at least 80% johnsongrass control at any rate or application timing tested. A single application of fluazifop-butyl provided greater than 90% johnsongrass control when applied at 210 g ai ha −1 to johnsongrass with fewer than 6 leaves. Weed size played a role in achieving high levels of johnsongrass control. Greater than 90% control was achieved when johnsongrass had 6 leaves or fewer at the initial application for the sequential application treatments. A single application of fluazifop-butyl at 105 g ai ha −1 resulted in no more than 82% johnsongrass mortality at any application timing. TamArk™ grain sorghum injury did not exceed 6% at any application timing or rate. It was therefore considered to be safe even if the initial application was made before the 6-leaf crop stage. Because no unacceptable levels of injury were observed with TamArk™ grain sorghum for fluazifop-butyl, johnsongrass size at the time of application should be the most critical aspect for control with this herbicide.
No takes yet. Share an insight, caveat, or question.
Fleming et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: